Expertise in
34
conditions

Dr. Byron Lam

Ophthalmology
Office
900 NW 17th St Ste 3, 
Miami, FL 
Offers Telehealth
Expertise in
34
conditions
Office
900 NW 17th St Ste 3, 
Miami, FL 

Overview

Byron Lam is an Ophthalmologist in Miami, Florida. Dr. Lam is highly rated in 34 conditions, according to our data. His top areas of expertise are X-Linked Retinitis Pigmentosa (XLRP), Retinitis Pigmentosa, Optic Nerve Atrophy, Vitrectomy, and Nerve Decompression.

His clinical research consists of co-authoring 202 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Ophthalmology

Licenses

Ophthalmology in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Office
900 NW 17th St Ste 3, Miami, FL 33136
Other Locations
Umhc-Sylvester Comprehensive Cancer Center
1475 NW 12th Ave, Miami, FL 33136

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA
An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Drug
Study Drug: Injection of scAAV2-P1ND4v2
Study Phase: Phase 1
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Enrollment Status: Enrolling_by_invitation
Publish Date: April 27, 2025
Intervention Type: Drug
Study Drug: ALK-001
Study Phase: Phase 2
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Atrophic Dry Age Related Macular Degeneration
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Atrophic Dry Age Related Macular Degeneration
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Enrollment Status: Terminated
Publish Date: July 12, 2024
Intervention Type: Drug, Other
Study Drug: Ultevursen
Study Phase: Phase 2/Phase 3
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drug: AGTC-402
Study Phase: Phase 1/Phase 2
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drug: rAAV2tYF-PR1.7-hCNGB3
Study Phase: Phase 1/Phase 2
Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss
Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss
Enrollment Status: Terminated
Publish Date: June 16, 2022
Intervention Type: Drug, Procedure
Study Phase: Phase 3
Natural History Study of CEP290-Related Retinal Degeneration
Natural History Study of CEP290-Related Retinal Degeneration
Enrollment Status: Completed
Publish Date: May 19, 2022
A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene
A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2022
Intervention Type: Drug, Other
Study Drug: QR-1123
Study Phase: Phase 1/Phase 2
Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

201 Total Publications

Very-Late-Onset Neuromyelitis Optica Spectrum Disorder Presenting as Isolated Optic Neuritis in an 85-Year-Old Woman: A Diagnostic and Management Challenge.
Very-Late-Onset Neuromyelitis Optica Spectrum Disorder Presenting as Isolated Optic Neuritis in an 85-Year-Old Woman: A Diagnostic and Management Challenge.
Journal: Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
Published: December 18, 2025
Similar Doctors
Expertise in
25
conditions
Dr. Harry Flynn
Ophthalmology
Expertise in
25
conditions
Dr. Harry Flynn
Ophthalmology

Bascom Palmer Eye Institute-Anne Bates Leach Eye Hospital

900 NW 17th St, 
Miami, FL 
 (0.1 miles away)
305-326-6000
Languages Spoken:
English
See accepted insurances

Harry Flynn is an Ophthalmologist in Miami, Florida. Dr. Flynn is highly rated in 25 conditions, according to our data. His top areas of expertise are Endophthalmitis, Retinal Detachment, Interstitial Keratitis, Vitrectomy, and Cataract Removal.

Expertise in
27
conditions
Dr. Thomas Albini
Ophthalmology
Expertise in
27
conditions
Dr. Thomas Albini
Ophthalmology

Bascom Palmer Eye Institute-Anne Bates Leach Eye Hospital

900 NW 17th St, 
Miami, FL 
 (0.1 miles away)
305-482-5006
Languages Spoken:
English
See accepted insurances

Thomas Albini is an Ophthalmologist in Miami, Florida. Dr. Albini is highly rated in 27 conditions, according to our data. His top areas of expertise are Endophthalmitis, Uveitis, CMV Retinitis, Vitrectomy, and Cataract Removal.

Expertise in
21
conditions
Dr. William Smiddy
Ophthalmology
Expertise in
21
conditions
Dr. William Smiddy
Ophthalmology

Bascom Palmer Eye Institute-Anne Bates Leach Eye Hospital

900 NW 17th St, 
Miami, FL 
 (0.1 miles away)
305-326-6000
Languages Spoken:
English
See accepted insurances

William Smiddy is an Ophthalmologist in Miami, Florida. Dr. Smiddy is highly rated in 21 conditions, according to our data. His top areas of expertise are Retinal Detachment, Endophthalmitis, Diabetic Retinopathy, Vitrectomy, and Trabeculectomy.

Frequently Asked Questions about Dr. Byron Lam

How do I make an appointment with Dr. Byron Lam?

You can book an appointment with Dr. Byron Lam by calling their office at 305-243-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Byron Lam a top-rated expert for X-Linked Retinitis Pigmentosa (XLRP)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Byron Lam is classified as an Elite expert for X-Linked Retinitis Pigmentosa (XLRP), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Byron Lam specialize in?

While Dr. Byron Lam is a Ophthalmology, they have specific expertise in X-Linked Retinitis Pigmentosa (XLRP), Retinitis Pigmentosa, and Optic Nerve Atrophy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Ophthalmology.

Does Dr. Byron Lam participate in research or clinical trials?

Yes. Dr. Byron Lam has published 201 articles and abstracts on conditions like X-Linked Retinitis Pigmentosa (XLRP). You can view a list of Dr. Byron Lam's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Byron Lam accept my insurance?

Dr. Byron Lam accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 305-243-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lam's expertise for a condition
ConditionClose
View All 17 Distinguished Conditions
View All 11 Advanced Conditions
View All 44 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile